Artelo Biosciences Inc 2025年季度报告

TRANSITION REPORT PERSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ofincorporation or organization) Solana Beach,CAUSA(Address of principal executive offices) (858)925-7049 Name of each exchange on which Trading Symbol(s)Common Stock, $0.001 par value perARTL Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and (2) has been subject to such filing requirements for the past 90 days.☒Yes reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Common stockPaid-inSharesAmountCapital Balance, December 31, 2023 Common shares issued for cash39-55--Stock based compensation--213--Net loss for the period---(2,483)-Balance, March 31, 20243,228$3$52,530$(42,793)$(203)$9,537 5 Three months endedMarch 31,2025CASH FLOWS FROM OPERATING ACTIVITIES Net change in fair value of trading marketable securitiesNon-cash lease expense Changes in operating assets and liabilities:Prepaid expenses and other current assets9Deferred offering costs(424)Accounts payable and accrued liabilities800Accounts payable - related parties(38)Advances from investors236Fixed cash payments related to operating leases(8)Net cash used in operating activities(1,597) Net cash provided by financing activities Effect of exchange rate changes on cash Net change in cash and cash equivalentsCash and cash equivalents - beginning of period Cash and cash equivalents - end of period$746$Supplemental Cash Flow InformationCash paid for interest$-$Cash paid for income taxes$-$ 6 NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESSARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011, and basedin San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally The Company registered wholly owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in theUnited Kingdom (“UK”), Trinity Research & Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research andDevelopment Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly owned subsidiary in statements. The Company is a clinical stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling pathways,including treatments intended to modulate the endocannabinoid system (the “ECS”), a family of receptors and neurotransmitters thatform a biochemical communication network throughout the body. The Company has incurred losses since inception and incurred a net loss of $2,372during the three months ended March 31, 2025.Asof March 31, 2025, we had cash and cash equivalents of $0.7million. In May 2022, the Company entered into a purchase agreementand a registration rights agreement (the “Equity Line”) with an institutional investor, providing for the sale of up to $20,000worth of limitations. In July 2023, the Company filed a $75,000in aggregate value shelf registration statement on Form S-3 which became effective on July14, 2023. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $75,000of the Company’s Common Stock, preferred stock, debt securities, warrants, and/or unitssubject to a limit of one-third (1/3) of the statements do not include any adjustments to reflect the future effects on the recoverability and classification of assets or the amountsand classification of liabilities if the Company is unable to continue as a going concern. Negative Global or National Events Businesses have been and will continue to be impacted by a number of challenging global and national events and circumstances thatcontinue to evolve, including tariffs, trade disputes, pandemics, extreme weather conditions, increased economic uncertainty, inflation,interest rate fluctuation, recent and any potential future financial institution failures, and conflicts in Eastern Europe, the Middle East timelines and plans remains uncertain, and will depend on certain developments, including the duration and scope of the events andtheir impact on our development activities, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. We have been and continue to actively monitor thepotential impacts that these various events and circumstances may have on our business, and we take steps, where warranted, tominimize any potential negative impacts on our business resulting from these events and circumstances. The ultimate impact of these global and national